Full text is available at the source.
Abstract
The study evaluates the relationship between starting glucagon-like peptide-1 receptor agonists and frailty progression compared to dipeptidyl peptidase-4 inhibitors.
- Initiating glucagon-like peptide-1 receptor agonists may be linked to changes in frailty status over time.
- The impact on frailty progression may differ based on the initial level of frailty.
- The comparison includes assessing the incidence of falls associated with each medication type.
Simplified